

# Jidong Jia

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4633140/jidong-jia-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140  
papers

3,107  
citations

24  
h-index

52  
g-index

160  
ext. papers

4,293  
ext. citations

6.2  
avg, IF

4.97  
L-index

#	Paper	IF	Citations
140	Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.. <i>Hepatology International</i> , <b>2022</b> , 16, 195	8.8	0
139	Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor.. <i>Stem Cell Research and Therapy</i> , <b>2022</b> , 13, 94	8.3	3
138	GITR/GITRL reverse signalling modulates the proliferation of hepatic progenitor cells by recruiting ANXA2 to phosphorylate ERK1/2 and Akt.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 297	9.8	
137	Adult-onset Type II Citrullinemia manifested as steatosis or steatohepatitis: a report of three Chinese cases.. <i>Journal of Digestive Diseases</i> , <b>2022</b> ,	3.3	
136	Non-invasive evaluation of esophageal varices in patients with liver cirrhosis using low-dose splenic perfusion CT.. <i>European Journal of Radiology</i> , <b>2022</b> , 152, 110326	4.7	0
135	Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by <i>Leishmania infantum</i> infection. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009944	4.8	0
134	Consensus on the secondary prevention of primary liver cancer. <i>Hepatology International</i> , <b>2021</b> , 15, 1289-1300	8.0	1
133	Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis. <i>Hepatology International</i> , <b>2021</b> , 15, 1318-1327	8.8	0
132	Advances in the diagnosis and treatment of viral hepatitis B and C in China.. <i>Chinese Medical Journal</i> , <b>2021</b> , 135, 379-380	2.9	
131	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2499-2513	6.9	10
130	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. <i>Hepatology International</i> , <b>2021</b> , 15, 611-620	8.8	0
129	Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. <i>Hepatology International</i> , <b>2021</b> , 15, 1122-1135	8.8	6
128	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 329-338	6.1	1
127	Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. <i>Clinical Liver Disease</i> , <b>2021</b> , 18, 18-21	2.2	1
126	A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1009-1019.e11	6.9	5
125	Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1423-1434	4	7
124	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , <b>2021</b> , 41, 369-377	7.9	3

123	Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma. <i>Cell Adhesion and Migration</i> , <b>2021</b> , 15, 249-260	3.2	0
122	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2375-2382	4	2
121	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 454-461	13.4	22
120	Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice. <i>American Journal of Pathology</i> , <b>2021</b> , 191, 1564-1579	5.8	2
119	Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	1
118	Correlation of genotype and phenotype in 32 patients with hereditary hemochromatosis in China. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 398	4.2	5
117	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , <b>2021</b> , 3, 100361	10.3	3
116	Impact of the Kasai Procedure and the Length of Native Liver Survival Time on Outcomes of Liver Transplantation for Biliary Atresia. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	1
115	Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. <i>The Lancet Regional Health - Western Pacific</i> , <b>2021</b> , 16, 100249	5	3
114	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , <b>2021</b> , 15, 82-92	8.8	0
113	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , <b>2020</b> , 24, 415-423	3.8	1
112	Irradiated and CCl <sub>4</sub> -treated bone marrow-derived liver macrophages exhibit different gene expression patterns and phenotypes. <i>Scandinavian Journal of Immunology</i> , <b>2020</b> , 92, e12916	3.4	1
111	FoxA2 inhibits the proliferation of hepatic progenitor cells by reducing PI3K/Akt/HK2-mediated glycolysis. <i>Journal of Cellular Physiology</i> , <b>2020</b> , 235, 9524-9537	7	6
110	Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. <i>Hepatology</i> , <b>2020</b> , 72, 729-741	11.2	35
109	A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 74	4.2	2
108	EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. <i>Histochemistry and Cell Biology</i> , <b>2020</b> , 154, 107-116	2.4	2
107	HFE-Related Hemochromatosis in a Chinese Patient: The First Reported Case. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 77	4.5	4
106	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2582-2591.e6	6.9	22

105	Critical role of OX40 in drug-induced acute liver injury. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 3183-3196	3.1	2
104	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , <b>2020</b> , 5, 1129-1138	4.1	6
103	A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFN $\alpha$ therapy in Chinese HBeAg-positive chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 469-478	6.1	3
102	Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 279-286	3.3	4
101	Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study. <i>Antiviral Therapy</i> , <b>2020</b> , 25, 293-304	1.6	1
100	Efficacy and Safety of All-oral Emtasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 255-261	5.2	
99	Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment. <i>China CDC Weekly</i> , <b>2020</b> , 2, 596-600	4	1
98	Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury. <i>Hepatology Research</i> , <b>2020</b> , 50, 224-232	5.1	3
97	Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. <i>Hepatology International</i> , <b>2020</b> , 14, 105-114	8.8	19
96	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
95	Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 391	3	2
94	Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 839-849	18.8	15
93	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 519-525	3.3	5
92	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
91	Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities. <i>JHEP Reports</i> , <b>2020</b> , 2, 100165	10.3	8
90	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1540-1550	6.1	6
89	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , <b>2020</b> , 48, 233-239	3	2
88	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. <i>Hepatology</i> , <b>2020</b> , 71, 463-476	11.2	14

87	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 196-204.e8	6.9	7
86	ECM1 Prevents Activation of Transforming Growth Factor $\beta$ Hepatic Stellate Cells, and Fibrogenesis in Mice. <i>Gastroenterology</i> , <b>2019</b> , 157, 1352-1367.e13	13.3	35
85	Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. <i>Hepatology International</i> , <b>2019</b> , 13, 788-799	8.8	18
84	Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. <i>Hepatology International</i> , <b>2019</b> , 13, 766-776	8.8	17
83	Complex ATP7B mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants. <i>Human Mutation</i> , <b>2019</b> , 40, 552-565	4.7	5
82	Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. <i>Journal of Digestive Diseases</i> , <b>2019</b> , 20, 467-475	3.3	3
81	Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1676-1684	4	17
80	SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. <i>Hepatology International</i> , <b>2019</b> , 13, 501-509	8.8	3
79	Dynamics of elastin in liver fibrosis: Accumulates late during progression and degrades slowly in regression. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 22613-22622	7	11
78	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , <b>2019</b> , 5, 915-916	13.4	2
77	Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. <i>Infection and Drug Resistance</i> , <b>2019</b> , 12, 745-757	4.2	8
76	On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon $\alpha$ add-on therapy. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1499-1509	19.7	2
75	Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly. <i>Liver International</i> , <b>2019</b> , 39, 389-400	7.9	13
74	Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. <i>Gastroenterology Research and Practice</i> , <b>2019</b> , 2019, 8959103	2	8
73	A multimodal international collaborative clinical research training program in China. <i>Medical Education Online</i> , <b>2019</b> , 24, 1679944	4.4	
72	Exosomal microRNA in autoimmunity. <i>Cellular and Molecular Immunology</i> , <b>2019</b> , 16, 932-934	15.4	16
71	A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 249-257	5.2	3
70	Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 221-225	5.2	8

69	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 213-220	5.2	9
68	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 322-328	5.2	2
67	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 929-937	0.7	25
66	Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. <i>Hepatology International</i> , <b>2019</b> , 13, 91-101	8.8	24
65	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 576-585	3.4	15
64	Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1236-1241	4	7
63	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1929-1936.e1	6.9	28
62	A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China. <i>Liver International</i> , <b>2019</b> , 39, 1120-1127	7.9	8
61	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 12-21	4	17
60	Ledipasvir/sofosbuvir for treatment-naïve and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. <i>Hepatology International</i> , <b>2018</b> , 12, 126-132	8.8	15
59	Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy. <i>Scientific Reports</i> , <b>2018</b> , 8, 2989	4.9	16
58	Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 1129-1137	6.9	28
57	How to control highly endemic hepatitis B in Asia. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 122-125	7.9	19
56	Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. <i>Hepatology International</i> , <b>2018</b> , 12, 118-125	8.8	13
55	Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. <i>International Journal of Infectious Diseases</i> , <b>2018</b> , 67, 58-64	10.5	4
54	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 282-294	12.3	26
53	Inorganic nitrate alleviates the senescence-related decline in liver function. <i>Science China Life Sciences</i> , <b>2018</b> , 61, 24-34	8.5	13
52	Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. <i>Modern Pathology</i> , <b>2018</b> , 31, 1191-1200	9.8	22

51	Platelets increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. <i>Hepatology International</i> , <b>2018</b> , 12, 237-243	8.8	12
50	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , <b>2018</b> , 48, E213-E221	5.1	14
49	Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. <i>Hepatology Research</i> , <b>2018</b> , 48, E283-E290	5.1	11
48	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 61-69	5.4	12
47	Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 201-209 <sup>1.6</sup>		7
46	Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2018</b> , 110, 557-563	0.9	12
45	On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1045-1054	7.9	23
44	OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis. <i>Cell Reports</i> , <b>2018</b> , 25, 3786-3799.e4	10.6	13
43	Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 4480-4495	8.6	11
42	Mutation analysis of the gene in Chinese patients with Dubin-Johnson syndrome. <i>Experimental and Therapeutic Medicine</i> , <b>2018</b> , 16, 4201-4206	2.1	7
41	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199198	3.7	4
40	Non- mutations in haemochromatosis in China: combination of heterozygous mutations involving signal peptide variants. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 650-660	5.8	16
39	Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. <i>Modern Pathology</i> , <b>2018</b> , 31, 1567-1577	9.8	9
38	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 52-62	18.8	43
37	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , <b>2017</b> , 11, 317-370	8.8	955
36	Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of golden window? A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1989-1997	4.7	31
35	New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. <i>Hepatology</i> , <b>2017</b> , 65, 1438-1450	11.2	75
34	Inhibitory effects of HNF4β on migration/maltransformation of hepatic progenitors: HNF4β overexpressing hepatic progenitors for liver repopulation. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 183	8.3	3

33	Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. <i>Hepatology International</i> , <b>2017</b> , 11, 461-471	8.8	81
32	A brief review on prognostic models of primary biliary cholangitis. <i>Hepatology International</i> , <b>2017</b> , 11, 412-418	8.8	10
31	Functional restoration of CD56 NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. <i>Hepatology International</i> , <b>2017</b> , 11, 419-428	8.8	5
30	Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. <i>International Journal of Molecular Medicine</i> , <b>2017</b> , 40, 454-464	4.4	17
29	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , <b>2017</b> , 5, 297-318	5.2	136
28	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 16498-16506	3.3	31
27	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , <b>2016</b> , 65, 313-20	19.2	85
26	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 700-710	13.4	236
25	Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. <i>Hepatology International</i> , <b>2016</b> , 10, 854-860	8.8	38
24	Enhanced Performance of Proliferation Assay of Bone Marrow Cells by Optimizing in vivo Incorporation of 5-Ethynyl-2'-Deoxyuridine and Cell Preparation for Flow Cytometry. <i>Analytical Letters</i> , <b>2016</b> , 49, 2132-2145	2.2	
23	Tanshinone IIA promotes the proliferation of WB-F344 hepatic oval cells via Wnt/ $\beta$ -catenin signaling. <i>Molecular Medicine Reports</i> , <b>2016</b> , 13, 1501-8	2.9	9
22	The Characteristics Variation of Hepatic Progenitors after TGF- $\beta$ -Induced Transition and EGF-Induced Reversion. <i>Stem Cells International</i> , <b>2016</b> , 2016, 6304385	5	5
21	A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. <i>International Journal of Environmental Research and Public Health</i> , <b>2016</b> , 13,	4.6	6
20	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , <b>2016</b> , 6, 37498	4.9	10
19	A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5391	1.8	15
18	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 674-682	13.4	27
17	Matrix metalloproteinase-1 induction by diethylthiocarbamate is regulated via Akt and ERK/miR222/ETS-1 pathways in hepatic stellate cells. <i>Bioscience Reports</i> , <b>2016</b> , 36,	4.1	14
16	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1860-1867	4	28

15	Chronic HBV: which pregnant women should be treated?. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 105-8	7.9	10
14	Autoimmune hepatitis: East meets west. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1230-6	4	30
13	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , <b>2015</b> , 5, 17123	4.9	13
12	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 748-55	4	21
11	Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144425	3.7	16
10	An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. <i>EBioMedicine</i> , <b>2015</b> , 2, 438-46	8.8	20
9	Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 756-62	4	57
8	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , <b>2014</b> , 8, 382-94	8.8	9
7	Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2014</b> , 38, 475-80	2.4	6
6	Incorrect calculation and inappropriate interpretation: accuracy of international guidelines for identifying significant fibrosis in e antigen-negative chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1407-9	6.9	1
5	Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections. <i>BMJ Open Gastroenterology</i> , <b>2014</b> , 1, e000010	3.9	2
4	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. <i>Hepatology</i> , <b>2014</b> , 59, 1283-92	11.2	62
3	The Role of Fibrocytes in Fibrogenic Liver Diseases. <i>Current Pathobiology Reports</i> , <b>2014</b> , 2, 191-199	2	1
2	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , <b>2013</b> , 2, 48-56	1.6	10
1	Reply:. <i>Hepatology</i> , <b>2008</b> , 47, 1425-1426	11.2	